Aberdeen Group (DTIL) reports 8.88% Precision BioSciences ownership in 13G filing

Rhea-AI Filing Summary

Aberdeen Group plc and abrdn Inc. have disclosed a significant ownership stake in Precision BioSciences Inc. (DTIL). The reporting entities beneficially own 2,138,603 shares of Precision BioSciences common stock, representing 8.88% of the outstanding shares of this class as of 12/31/2025. They report zero sole voting or dispositive power, and shared voting and shared dispositive power over all 2,138,603 shares.

The firms state that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Precision BioSciences, nor in connection with any transaction intended to have that effect. abrdn Inc. indicates that it beneficially owns these shares on behalf of underlying clients, with Aberdeen Group plc as the parent company and abrdn Holdings Limited as intermediate holding company.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

PRECISION BIOSCIENCES INC

(Name of Issuer)

Common Stock, par value $0.000005 per share

(Title of Class of Securities)

74019P207

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Aberdeen Group plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,138,603.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,138,603.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,138,603.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.88 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

abrdn Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,138,603.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,138,603.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,138,603.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.88 %

12

Type of Reporting Person (See Instructions)

CO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PRECISION BIOSCIENCES INC
(b)	Address of issuer's principal executive offices: 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NORTH CAROLINA 27701
Item 2.
(a)	Name of person filing: Aberdeen Group plc abrdn Inc.
(b)	Address or principal business office or, if none, residence: Aberdeen Group plc 1 George Street Edinburgh, United Kingdom EH2 2LL abrdn inc 1900 Market Street Suite 200, Philadelphia, PA 19103
(c)	Citizenship: Aberdeen Group plc - UNITED KINGDOM abrdn Inc. - UNITED STATES
(d)	Title of class of securities: Common Stock, par value $0.000005 per share
(e)	CUSIP No.: 74019P207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,138,603
(b)	Percent of class: 8.88 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Aberdeen Group plc - 0 abrdn Inc. - 0
	(ii) Shared power to vote or to direct the vote: Aberdeen Group plc - 2,138,603 abrdn Inc. - 2,138,603
	(iii) Sole power to dispose or to direct the disposition of: Aberdeen Group plc - 0 abrdn Inc. - 0
	(iv) Shared power to dispose or to direct the disposition of: Aberdeen Group plc - 2,138,603 abrdn Inc. - 2,138,603
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aberdeen Group plc

Signature:	J. Clarke
Name/Title:	Jenny Clarke/Major Shareholding Reporting Analyst
Date:	01/16/2026

abrdn Inc.

Signature:	J. Clarke
Name/Title:	Jenny Clarke/Major Shareholding Reporting Analyst
Date:	01/16/2026

Exhibit Information

Aberdeen Group plc abrdn Holdings Limited abrdn Inc. Aberdeen Group plc is the parent company. abrdn Holdings Limited is the intermediate holding company for abrdn Inc. abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

FAQ

What percentage of Precision BioSciences (DTIL) does Aberdeen Group plc beneficially own?

Aberdeen Group plc and abrdn Inc. report beneficial ownership of 2,138,603 shares of Precision BioSciences common stock, representing 8.88% of the outstanding shares of that class as of 12/31/2025.

How many Precision BioSciences (DTIL) shares are reported in this Schedule 13G?

The filing reports 2,138,603 Precision BioSciences common shares as beneficially owned, with shared voting power and shared dispositive power over all of these shares and no sole voting or dispositive power.

Who are the reporting persons in this Precision BioSciences (DTIL) Schedule 13G?

The reporting persons are Aberdeen Group plc and abrdn Inc., with Aberdeen Group plc as the parent company and abrdn Holdings Limited as the intermediate holding company for abrdn Inc.

Is Aberdeen’s stake in Precision BioSciences (DTIL) held to influence control of the company?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Precision BioSciences, nor in connection with any transaction having that purpose or effect.

On whose behalf does abrdn Inc. hold its Precision BioSciences (DTIL) shares?

The exhibit explains that abrdn Inc. beneficially owns 5% or greater of the outstanding shares of this security class on behalf of its underlying clients.

What class of securities of Precision BioSciences (DTIL) is covered in this Schedule 13G?

The filing covers Common Stock of Precision BioSciences Inc., with a par value of $0.000005 per share and CUSIP number 74019P207.